KTTA Stock Forecast: Pasithea Therapeutics Corp. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.48
−0.48% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 13 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$17.6M
Ticker Nerd rank
13/ 100
Median analyst target
$4.00
Analysts covering
—
Revenue$0.0
Operating income−$5.7M
Net income−$5.3M
Free cash flow−$4.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.3%
1M
+16.8%
YTD
−62.9%
1Y
+15.3%
From 52W high
−67.4%
From 52W low
+63.9%
$0.29
$1.47
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Pasithea Therapeutics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
13/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
48
Accruals
41
Growth
25
Issuance
23
Quality
22
Momentum
17
Volatility
13
Value
9

Revisions (48): Analysts have, on balance, been raising their forecasts.

Value (9): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

KTTA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KTTA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00Jan 26Apr 26Jul 26Oct 26KTTAHigh $4.00Median $4.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Nov 2026HC Wainwright & Co.MaintainsBuy$3.00 → $4.00
16 June 2026HC Wainwright & Co.ReiteratesBuy$3.00
20 Apr 2026HC Wainwright & Co.ReiteratesBuy—
8 Dec 2025HC Wainwright & Co.InitiatesBuy—
10 July 2023EF HuttonReiteratesBuy$2.00
1 June 2023EF HuttonAssumesBuy$2.00
3 Apr 2023EF HuttonMaintainsBuy$2.30 → $2.00
14 Dec 2021EF HuttonInitiatesBuy$3.25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

KTTA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

KTTA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Pasithea Therapeutics Corp. returned +15.3% against +6.9% for the S&P 500, dividends included.

KTTA vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250300350400Jan 26Apr 26Jul 26Oct 26KTTAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KTTA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.4×

Cheaper than 90% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−88.8%

Higher than 15% of US stocks

Return on assets
−49.2%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Pasithea Therapeutics Corp. has a market value of $17.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$21.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$17.8M.

  • Shares outstanding: 33.4M.

  • Pasithea Therapeutics Corp. employs 5 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

KTTA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KTTAPasithea Therapeutics Corp.$17.6M13
MRKRMarker Therapeutics, Inc.$18.2M76
COCPCocrystal Pharma, Inc.$18.3M48
LPCNLipocine, Inc.$16.4M39
ATOSAtossa Therapeutics, Inc.$15.9M22
IGCIGC Pharma, Inc.$19.5M14
PBMPsyence Biomedical Ltd.$15.8M4

Take a look at KTTA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Pasithea Therapeutics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about KTTA

How does Ticker Nerd's model rank KTTA?

As at 21 Nov 2026, Pasithea Therapeutics Corp. ranks 13 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (48 of 100).

What is the KTTA stock forecast for 2030?

No analyst covering Pasithea Therapeutics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KTTA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.

How has KTTA stock performed over the past year?

Pasithea Therapeutics Corp. returned +15.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pasithea Therapeutics Corp. do?

Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system disorders and RASopathies. The company’s current programs center on PAS-004, a next-generation macrocyclic MEK inhibitor being developed for indications that include neurofibromatosis type 1-associated plexiform neurofibromas and selected oncology uses.

Company

About Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system disorders and RASopathies. The company’s current programs center on PAS-004, a next-generation macrocyclic MEK inhibitor being developed for indications that include neurofibromatosis type 1-associated plexiform neurofibromas and selected oncology uses. Pasithea Therapeutics Corp. also works on additional therapeutic candidates aimed at neurological and psychiatric conditions, reflecting a broader emphasis on diseases with significant unmet medical need. The company operates through therapeutic development activities and clinic-related services, positioning itself across both drug research and patient-facing healthcare applications. Based in Miami Beach, Florida, Pasithea Therapeutics Corp. plays a role in the clinical-stage biotechnology market by advancing targeted treatment candidates for complex disorders.

CEO Dr. Tiago Reis Marques M.D., Ph.D. · 5 employees · United States · https://www.pasithea.com